Literature DB >> 29330291

Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions.

Bo Wu1,2,3, Shu Yang1,2,3, Haimei Sun1,2,3, Tingyi Sun1,2,3, Fengqing Ji1,2,3, Yurong Wang1, Lie Xu1, Deshan Zhou4,2,3.   

Abstract

Low expression of the tumor suppressor Kelch-like ECH-associated protein 1 (KEAP1) in non-small cell lung cancer (NSCLC) often results in higher malignant biological behavior and poor prognosis; however, the underlying mechanism remains unclear. The present study demonstrates that overexpression of Keap1 significantly suppresses migration and invasion of three different lung cancer cells (A549, H460, and H1299). Highly expressed Keap1, compared with the control, promotes formation of multiple stress fibers with larger mature focal adhesion complexes in the cytoplasm where only fine focal adhesions were observed in the membrane under control conditions. RhoA activity significantly increased when Keap1 was overexpressed, whereas Myosin 9b expression was reduced but could be rescued by proteasome inhibition. Noticeably, mouse tumor xenografts with Keap1 overexpression were smaller in size and less metastatic relative to the control group. Taken together, these results demonstrate that Keap1 stabilizes F-actin cytoskeleton structures and inhibits focal adhesion turnover, thereby restraining the migration and invasion of NSCLC. Therefore, increasing Keap1 or targeting its downstream molecules might provide potential therapeutic benefits for the treatment of patients with NSCLC.Implications: This study provides mechanistic insight on the metastatic process in NSCLC and suggests that Keap1 and its downstream molecules may be valuable drug targets for NSCLC patients. Mol Cancer Res; 16(3); 508-16. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29330291     DOI: 10.1158/1541-7786.MCR-17-0544

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  7 in total

1.  Targeted substrate degradation by Kelch controls the actin cytoskeleton during ring canal expansion.

Authors:  Andrew M Hudson; Katelynn M Mannix; Julianne A Gerdes; Molly C Kottemann; Lynn Cooley
Journal:  Development       Date:  2019-01-02       Impact factor: 6.868

Review 2.  Beyond repression of Nrf2: An update on Keap1.

Authors:  Aleksandra Kopacz; Damian Kloska; Henry Jay Forman; Alicja Jozkowicz; Anna Grochot-Przeczek
Journal:  Free Radic Biol Med       Date:  2020-03-28       Impact factor: 7.376

3.  Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.

Authors:  Haipeng Huang; Yunhong Wu; Weijin Fu; Xiaoming Wang; Liquan Zhou; Xiaolong Xu; Fu Huang; Yi Wu
Journal:  Int J Mol Med       Date:  2019-03-14       Impact factor: 4.101

Review 4.  Involvement of the Actin Machinery in Programmed Cell Death.

Authors:  Weida Ren; Wanyu Zhao; Lingbo Cao; Junqi Huang
Journal:  Front Cell Dev Biol       Date:  2021-02-09

5.  Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring KEAP1/NFE2L2.

Authors:  Xiaodong Yang; Ming Li; Zhencong Chen; Xiaobin Fan; Liang Guo; Bo Jin; Yiwei Huang; Qun Wang; Liang Wu; Cheng Zhan
Journal:  J Cancer       Date:  2022-02-28       Impact factor: 4.207

6.  Diagnostic and Prognostic Significance of Keap1 mRNA Expression for Lung Cancer Based on Microarray and Clinical Information from Oncomine Database.

Authors:  Guang-Ya Liu; Wei Zhang; Xu-Chi Chen; Wen-Juan Wu; Shi-Qian Wan
Journal:  Curr Med Sci       Date:  2021-06-25

7.  Agonist Effects of Propranolol on Non-Tumor Human Breast Cells.

Authors:  Lucía Gargiulo; Ezequiel Mariano Rivero; Nicolás di Siervi; Edgardo David Buzzi; Mariano Gabriel Buffone; Carlos Alberto Davio; Isabel Alicia Lüthy; Ariana Bruzzone
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.